Agreed—drugs like Xarelto and Apixaban can become very big sellers from the venous side alone. The question I was raising in the previous post is whether these pure FXa inhibitors have the potential to render such drugs as Lovenox (and MNTA’s M118) superfluous. I think the answer is No.
Market Data 
Markets 
AI
